🇺🇸 FDA
Patent

US 9949962

Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases

granted A61KA61K31/454A61P

Quick answer

US patent 9949962 (Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases) held by OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES” expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”
Grant date
Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/454, A61P, A61P1/00, A61P1/04